The Food and Drug Administration’s (FDA) integration of artificial intelligence (AI) into drug development and manufacturing is expanding rapidly, but the agency recently advised at its annual regulatory conference that this innovation must not compromise quality or compliance. While AI can significantly enhance efficiency in data analysis and submission processes, the agency emphasized it cannot serve as a substitute for human expert judgment, regulatory knowledge, or rigorous quality oversight. The FDA stated that companies remain fully accountable for all AI-generated content, as evidenced by a recent warning letter issued to a manufacturer for using AI to create production records and drug specifications without ensuring their accuracy or compliance with good manufacturing practice (CGMP). Ultimately, the agency cautioned that treating AI as a substitute for human oversight may constitute a GCMP violation. Learn more about FDA’s AI regulatory strategies.
Last Updated on June 12, 2026 by Aimed Alliance
